Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.

Tamura T, Toyokawa T, Lee S, Ishidate T, Sakurai K, Kubo N, Deguchi S, Seki Y, Kuroda K, Kasashima H, Miki Y, Yoshii M, Shibutani M, Ohira M, Maeda K

Open source

DOI: 10.21873/anticanres.18302
Published: 2026 Aug
Container: Anticancer research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21873/anticanres.18302,
  title = {Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.},
  author = {Tamura T and Toyokawa T and Lee S and Ishidate T and Sakurai K and Kubo N and Deguchi S and Seki Y and Kuroda K and Kasashima H and Miki Y and Yoshii M and Shibutani M and Ohira M and Maeda K},
  year = {2026},
  journal = {Anticancer research},
  doi = {10.21873/anticanres.18302},
  url = {https://doi.org/10.21873/anticanres.18302}
}

RIS

TY  - JOUR
TI  - Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
AU  - Tamura T
AU  - Toyokawa T
AU  - Lee S
AU  - Ishidate T
AU  - Sakurai K
AU  - Kubo N
AU  - Deguchi S
AU  - Seki Y
AU  - Kuroda K
AU  - Kasashima H
AU  - Miki Y
AU  - Yoshii M
AU  - Shibutani M
AU  - Ohira M
AU  - Maeda K
PY  - 2026
JO  - Anticancer research
DO  - 10.21873/anticanres.18302
UR  - https://doi.org/10.21873/anticanres.18302
ER  -

APA

T, T., T, T., S, L., T, I., K, S., N, K., S, D., Y, S., K, K., H, K., Y, M., M, Y., M, S., M, O., & K, M. (2026). Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.. Anticancer research. https://doi.org/10.21873/anticanres.18302

Source records

pubmed · retrieved 2026-09-26T21:00:45.871Z